×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
SNDX – syndax pharmaceuticals, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
SNDX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/3
04:05 pm
sndx
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Medium
Report
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
12/19
10:37 am
sndx
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) for Potential Breaches of Fiduciary Duty By Its Board of Directors
Low
Report
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) for Potential Breaches of Fiduciary Duty By Its Board of Directors
12/10
08:01 am
sndx
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $51.00 price target on the stock.
Medium
Report
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $51.00 price target on the stock.
12/9
07:42 am
sndx
Syndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial [Yahoo! Finance]
High
Report
Syndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial [Yahoo! Finance]
12/9
07:30 am
sndx
Syndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial
Medium
Report
Syndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial
12/7
06:18 pm
sndx
Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting [Yahoo! Finance]
Medium
Report
Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting [Yahoo! Finance]
12/7
06:15 pm
sndx
Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting
Medium
Report
Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting
12/4
01:52 pm
sndx
Why Is Syndax Pharmaceuticals, Inc. (SNDX) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? [Yahoo! Finance]
Low
Report
Why Is Syndax Pharmaceuticals, Inc. (SNDX) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
11/5/2024
04:01 pm
sndx
syndax pharmaceuticals, inc.
BEAT
Report
8.4%
syndax pharmaceuticals, inc.
8/1/2024
04:05 pm
sndx
syndax pharmaceuticals, inc.
BEAT
Report
-5.1%
syndax pharmaceuticals, inc.
5/8/2024
07:06 am
sndx
syndax pharmaceuticals, inc.
BEAT
Report
-2.7%
syndax pharmaceuticals, inc.
2/27/2024
04:05 pm
sndx
syndax pharmaceuticals, inc.
MISS
Report
-2.2%
syndax pharmaceuticals, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/20
05:00 pm
sndx
Form 8-K Syndax Pharmaceuticals For: Dec 20
Low
Report
Form 8-K Syndax Pharmaceuticals For: Dec 20
12/6
04:29 pm
sndx
Form SC 13G/A Syndax Pharmaceuticals Filed by: BlackRock, Inc.
Medium
Report
Form SC 13G/A Syndax Pharmaceuticals Filed by: BlackRock, Inc.
11/18
07:31 am
sndx
Form 8-K Syndax Pharmaceuticals For: Nov 15
Medium
Report
Form 8-K Syndax Pharmaceuticals For: Nov 15
11/12
09:24 am
sndx
Form 8-K Syndax Pharmaceuticals For: Nov 12
Low
Report
Form 8-K Syndax Pharmaceuticals For: Nov 12
11/8
05:34 pm
sndx
Form SC 13G/A Syndax Pharmaceuticals Filed by: BlackRock, Inc.
Low
Report
Form SC 13G/A Syndax Pharmaceuticals Filed by: BlackRock, Inc.
11/8
10:53 am
sndx
Form SC 13G/A Syndax Pharmaceuticals Filed by: WELLINGTON MANAGEMENT GROUP LLP
Low
Report
Form SC 13G/A Syndax Pharmaceuticals Filed by: WELLINGTON MANAGEMENT GROUP LLP
11/5
04:04 pm
sndx
Form 10-Q Syndax Pharmaceuticals For: Sep 30
Medium
Report
Form 10-Q Syndax Pharmaceuticals For: Sep 30
11/5
04:02 pm
sndx
Form 8-K Syndax Pharmaceuticals For: Nov 05
Medium
Report
Form 8-K Syndax Pharmaceuticals For: Nov 05
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/27
Syndax Pharmaceuticals Announces Preclinical Profile and Initial Phase 1 Data Demonstrating Clinical Activity of Menin Inhibitor SNDX-5613 in Adults with Relapsed/Refractory Acute Leukemias
69.4%
5/6 Form 8-K Syndax Pharmaceuticals For: May 06 35.6%
1/31 Syndax Announces $35.0 Million Offering of Common Stock and Enters Term Sheet for Loan with Hercules Capital for up to $30 Million 34.0%
3/3 Syndax Pharmaceuticals Reports Fourth Quarter 2019 Financial Results and Provides Clinical and Business Update 21.7%
2/4 Form 8-K Syndax Pharmaceuticals For: Jan 30 17.6%
4/14 Syndax Pharmaceuticals Announces Three Presentations at the 2020 American Association for Cancer Research Virtual Annual Meeting 12.6%
3/24 Syndax Pharmaceuticals Inc (NASDAQ: SNDX) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 11.1%
11/8 Syndax Pharmaceuticals, Inc. 2019 Q3 - Results - Earnings Call Presentation [Seeking Alpha] 8.1%
10/11 Form 4 Syndax Pharmaceuticals For: Oct 10 Filed by: Morrison Briggs 6.7%
8/7 Form S-8 Syndax Pharmaceuticals 6.3%
5/6 Form 8-K Syndax Pharmaceuticals For: May 06 35.6%
1/31 Syndax Announces $35.0 Million Offering of Common Stock and Enters Term Sheet for Loan with Hercules Capital for up to $30 Million 34.0%
3/3 Syndax Pharmaceuticals Reports Fourth Quarter 2019 Financial Results and Provides Clinical and Business Update 21.7%
2/4 Form 8-K Syndax Pharmaceuticals For: Jan 30 17.6%
4/14 Syndax Pharmaceuticals Announces Three Presentations at the 2020 American Association for Cancer Research Virtual Annual Meeting 12.6%
3/24 Syndax Pharmaceuticals Inc (NASDAQ: SNDX) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 11.1%
11/8 Syndax Pharmaceuticals, Inc. 2019 Q3 - Results - Earnings Call Presentation [Seeking Alpha] 8.1%
10/11 Form 4 Syndax Pharmaceuticals For: Oct 10 Filed by: Morrison Briggs 6.7%
8/7 Form S-8 Syndax Pharmaceuticals 6.3%
TOP News Decliners
2/15
Form 4 Syndax Pharmaceuticals For: Feb 12 Filed by: Legault Pierre
-8.5%
2/4 Syndax Pharmaceuticals Inc (NASDAQ: SNDX) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. -7.6%
10/7 Form 8-K Syndax Pharmaceuticals For: Oct 07 -6.1%
4/30 Form 8-K Syndax Pharmaceuticals For: Apr 30 -5.9%
8/9 Syndax Pharmaceuticals Inc (NASDAQ: SNDX) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -5.8%
3/12 Syndax Pharmaceuticals Inc (NASDAQ: SNDX) had its price target raised by analysts at Citigroup Inc from to . -5.7%
8/13 Syndax Pharmaceuticals (SNDX) Investor Presentation - Slideshow [Seeking Alpha] -5.0%
2/6 Form SC 13G/A Syndax Pharmaceuticals Filed by: BlackRock Inc. -4.8%
2/20 Form 8-K Syndax Pharmaceuticals For: Feb 12 -4.3%
8/28 Syndax Announces Participation at Four Upcoming Investor Conferences -4.0%
2/4 Syndax Pharmaceuticals Inc (NASDAQ: SNDX) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. -7.6%
10/7 Form 8-K Syndax Pharmaceuticals For: Oct 07 -6.1%
4/30 Form 8-K Syndax Pharmaceuticals For: Apr 30 -5.9%
8/9 Syndax Pharmaceuticals Inc (NASDAQ: SNDX) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -5.8%
3/12 Syndax Pharmaceuticals Inc (NASDAQ: SNDX) had its price target raised by analysts at Citigroup Inc from to . -5.7%
8/13 Syndax Pharmaceuticals (SNDX) Investor Presentation - Slideshow [Seeking Alpha] -5.0%
2/6 Form SC 13G/A Syndax Pharmaceuticals Filed by: BlackRock Inc. -4.8%
2/20 Form 8-K Syndax Pharmaceuticals For: Feb 12 -4.3%
8/28 Syndax Announces Participation at Four Upcoming Investor Conferences -4.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: